	US 11,793,756 B2
	Anionic nanocomplexes for nucleic acid delivery
Stephen Hart, London (GB); and Aristides Tagalakis, London (GB)
Assigned to UCL Business PLC, Greater London (GB)
Appl. No. 16/961,188
Filed by UCL Business PLC, London (GB)
PCT Filed Jan. 10, 2019, PCT No. PCT/GB2019/050066 § 371(c)(1), (2) Date Jul. 9, 2020, PCT Pub. No. WO2019/138235, PCT Pub. Date Jul. 18, 2019.
Claims priority of application No. 1800370 (GB), filed on Jan. 10, 2018.
Prior Publication US 2021/0052496 A1, Feb. 25, 2021
Int. Cl. A61K 9/127 (2006.01); A61P 35/00 (2006.01); A61K 31/7088 (2006.01); A61K 38/17 (2006.01)

CPC A61K 9/1271 (2013.01) [A61K 31/7088 (2013.01); A61K 38/1709 (2013.01); A61P 35/00 (2018.01)]

16 Claims

1. A non-viral delivery complex, comprising:

A, a cationic core which is a nanoparticle comprising:

(i) a peptide of formula A-B—C wherein A is a polycationic nucleic acid binding component, B is a spacer element that is susceptible to cleavage within a cell, and C is a cell surface receptor binding component,

(ii) a nucleic acid, and

(iii) a cationic lipid; and

B, an anionic coating which is a liposome surrounding the cationic core and which comprises lipids previously extracted from a plasma membrane of a subject's cells or exosomes or derivatives thereof.